Evidence map›Paper›PMID 42037974›Full record

ArticleCureus2026

Hepatic Myeloid Sarcoma Presenting With Recurrent Ascites: A Case Report.

Mossaab El Mousadik, Monsif Fadi, Zoubida Saad, Najat Lamalmi, Nouama Bouanani

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mossaab El MousadikClinical Hematology and Cellular Therapy, Mohammed VI University Hospital Center, Ibn Zohr University, Agadir, MAR.
Monsif FadiOncopathology, Cancer Biology, and Environment Laboratory, Mohammed VI Faculty of Medicine, Center for Doctoral Studies (CEDoc), Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR.
Zoubida SaadHematology, Faculty of Medicine, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR.
Najat LamalmiPathology, Ibn Sina University Hospital Center, Rabat, MAR.
Nouama BouananiHematology, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid sarcoma (MS) is an extramedullary manifestation of acute myeloid leukemia (AML) that may occur de novo, precede, or accompany AML. Hepatic involvement is rare and poses a diagnostic challenge. We report a 65-year-old man presenting with progressive abdominal distension, massive ascites, and constitutional symptoms. Initial laboratory tests revealed bicytopenia, leukocytosis, circulating immature granulocytes, and a cholestatic pattern on liver function tests. Imaging showed homogeneous hepatomegaly with large-volume ascites. Liver biopsy demonstrated diffuse infiltration by immature myeloid cells, with immunohistochemical positivity for myeloperoxidase (MPO) and CD117. Bone marrow (BM) cytogenetic analysis revealed an isochromosome 17q, supporting the diagnosis of hepatic MS, associated with an underlying clonal myeloid neoplasm. The patient received azacitidine and venetoclax, with no response, followed by cytarabine and daunorubicin, with transient clinical improvement; however, progression to AML occurred within a few weeks. This case highlights the diagnostic challenge of hepatic MS presenting as refractory ascites, and supports consideration of early liver biopsy, with sampling from multiple sites, in patients with unexplained ascites and underlying hematologic abnormalities.

Indexed as

acute myeloid leukemiahepatic malignancymyeloid neoplasmmyeloid sarcomarefractory ascites

Identifiers

PMID42037974
PMCPMC13109855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.